Wednesday, October 22, 2014 Last update: 6:33 PM
FreshNews.com - Covering Large & Obscure Tech Companies Since 1996

XenoPort to Release Second Quarter Financial Results on August 6, 2014

Companies mentioned in this article: XenoPort, Inc.

SANTA CLARA, Calif. -- (BUSINESS WIRE) -- XenoPort, Inc. (Nasdaq:XNPT) announced today that it will release its second quarter financial results on August 6, 2014 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day. A replay of the call will be available for one week following the event.

To access the conference call via the Internet, go to www.XenoPort.com. Please join the call at least 15 minutes prior to the start to ensure time for any software downloads that may be required.

To access the live conference call via phone, dial 1-888-275-3514. International callers may access the live call by dialing 706-679-1417. The reference number to enter the call is 72884596.

The replay of the conference call may be accessed that same day after 8:00 p.m. Eastern Time, via the Internet, at www.XenoPort.com, or via phone at 1-855-859-2056 for domestic callers, or 404-537-3406 for international callers. The reference number to enter the replay of the call is 72884596.

About XenoPort

XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. XenoPort is currently commercializing HORIZANT® (gabapentin enacarbil) Extended-Release Tablets in the United States and developing its novel fumaric acid ester product candidate, XP23829, as a potential treatment for moderate-to-severe chronic plaque type psoriasis and/or relapsing forms of multiple sclerosis. REGNITE® (gabapentin enacarbil) Extended-Release Tablets is being marketed in Japan by Astellas Pharma Inc. XenoPort recently granted exclusive world-wide rights for the development and commercialization of its clinical-stage oral product candidate, arbaclofen placarbil, to Reckitt Benckiser Pharmaceuticals, Inc. for all indications. To learn more about XenoPort, please visit the website at www.XenoPort.com.

XENOPORT, HORIZANT and REGNITE are registered trademarks of XenoPort, Inc.

XNPT2F


Copyright © Business Wire 2014
Contact:

XenoPort, Inc.
Jackie Cossmon, 408-616-7295
ir@XenoPort.com